Impact of Long-Term Warfarin Treatment on EVAR Durability: A Meta-Analysis

Abstract

Long-term anticoagulation in EVAR patients was associated with a statistically significant increase in any endoleak and persisting type II endoleaks, although it was not linked to an increased risk of reintervention. Close monitoring for EVAR patients who require long-term oral anticoagulation is advised.

The Influence of Preoperative Aneurysmal Thrombus Quantity and Distribution on the Development of Type II Endoleaks with Aneurysm Sac Enlargement After EVAR of AAA

“…Some authors stated that Warfarin and antiplatelet therapies are not associated with increased incidence of endoleak or aneurysm sac expansion [32,33]. Other works reported that anticoagulation or antiplatelet therapies appear to be linked to an increased risk for the development of type II endoleak or sac enlargement [22,34,35]. However, in our study, univariate analysis showed that only a combination of antiplatelet therapy and coumarine was associated with type II endoleak and aneurysm sac enlargement (4 of 10 patients).…”

Impact of Age and Intraluminal Thrombus Volume on Abdominal Aortic Aneurysm Sac Enlargement after Endovascular Repair

“…17,18 On the other hand, anticoagulation therapy was reported to be a risk for residual endoleak and sac expansion. 19,20 However, some recent studies including this study demonstrated that warfarin therapy was not associated with increased incidence of endoleaks and sac enlargement. 21,22 Although we think that the development of devices may reduce the risk of endoleaks and sac expansion in patients requiring anticoagulation therapy, there is still argument in this topic.…”

Association between Atrial Fibrillation and Aortic Aneurysms: A Population-Based Cohort Study

“…Although certain medications, such as statins, renin-angiotensin-aldosterone inhibitors, and CCBs, have been shown to limit or attenuate experimental AAA in animal models [34-36], three recent trials reported no benefit of the antibiotic doxycycline, a mast cell inhibitor, an angiotensin-converting enzyme inhibitor, or a CCB in limiting AAA growth [37, 38]. There is no evidence that commonly used cardiovascular drugs have beneficial effects on AA progression [39, 40] Long-term warfarin treatment in endovascular aneurysm repair patients was associated with a statistically significant increase in endoleaks and persistent type II endoleaks, although it was not linked to an increased risk of reintervention [41, 42]. Nevertheless, we found that no medication was protective against AAA in the present study.…”